Newswise — LOS ANGELES ― The University of Southern California (USC) Norris Comprehensive Cancer Center is actively recruiting for a clinical trial that is researching the effectiveness of a breath test for breast cancer diagnostics. The BreathLink™ device, manufactured by Menssana Research, Inc., captures a two-minute sample of a patient’s breath and provides immediate results on whether there are indications of breast cancer. If proven effective, the test would be used in conjunction with mammograms to rule out false-positive tests, sparing patients the pain, cost and anxiety of unnecessary biopsies.
“Diagnosing breast cancer requires the utmost vigilance, but we need to temper this vigilance with accuracy to prevent unnecessary testing,” said Linda Hovanessian-Larsen, MD, associate professor of clinical radiology and director of Women’s Imaging at the Keck School of Medicine of USC. Larsen is leading the trial at USC Norris and focuses much of her research to improving the accuracy and efficiency of breast cancer diagnostic techniques. “This kind of technology would be a welcome asset to our field, and we are eager to assess the safety and efficacy of this test.”
BreathLink is a non-invasive testing device that collects, concentrates and analyzes the organic compounds in a patient’s breath sample within minutes. Additionally, test results are uploaded to Menssana’s laboratory in New Jersey. While the test cannot diagnose disease, it can indicate if the patient should undergo further testing, which can save time and money while preventing additional emotional distress. Current research is evaluating the device’s effectiveness in lung cancer, breast cancer, heart transplant rejection, radiation exposure and pulmonary tuberculosis. The device is not yet approved by the Food and Drug Administration.
USC Norris is the first of five cancer centers in the United States participating in the trial, and the only center in California. The trial is partially funded by the National Institutes of Health and currently open to women who have a breast-related concern that requires mammography. This includes patients who require short term follow-up or additional workup from screenings, as well as women who exhibit clinical symptoms such as a breast lump. Women interested in enrolling in the trial can contact (323) 369-7775.
Research reported in this press was supported by National Cancer Institute of the National Institutes of Health under award number R44CA203019.
# # #
USC Norris Comprehensive Cancer Center has been leading the fight to make cancer a disease of the past. As one of the eight original comprehensive cancer centers in the United States, its mission is to treat and prevent cancer by advancing and integrating education, research and personalized patient care. For more than 40 years, USC Norris has been revolutionizing cancer research with innovative surgical techniques and novel cancer treatments. The cancer center's breakthroughs and discoveries in the field of epigenetics have led the way to a greater understanding of the underlying causes of cancer and new methods of prevention, detection, and treatment. With a multidisciplinary team of more than 250 dedicated scientists and physicians, USC Norris Comprehensive Cancer Center offers patients hope in the battle against cancer.
In 2016, U.S. News & World Report ranked USC Norris among the Top 20 hospitals in the United States for cancer care.
For more information, go to cancer.keckmedicine.org
MEDIA CONTACTRegister for reporter access to contact details